Completed PHASE2 INTERVENTIONAL 1-arm NCT00308074

An Open-Label Trial of Aripiprazole in Autism Spectrum Disorders

A Prospective Open-Label Trial of Aripiprazole Monotherapy in the Autism Spectrum Disorders (ASD)

Sponsor: Bristol-Myers Squibb

Conditions Asperger's Disorder Autism Pervasive Developmental Disorder

Updated 6 times since 2017 Last updated: Dec 30, 2016 Started: Feb 28, 2006 Primary completion: Dec 31, 2008 Completion: Feb 28, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Asperger's Disorder and Autism, this trial is completed. The trial is conducted by Bristol-Myers Squibb and has accumulated 6 data snapshots since 2006. Psychiatric clinical trials are essential for establishing evidence-based treatment standards.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Feb 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bristol-Myers Squibb
Cambridge Health Alliance

Data source: Cambridge Health Alliance

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Medford, United States